This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Topical Steroid Treatment After Posterior Lamellar Corneal Transplantation

This study has been withdrawn prior to enrollment.
Information provided by (Responsible Party):
Anders Ivarsen, Aarhus University Hospital Identifier:
First received: September 4, 2012
Last updated: April 30, 2014
Last verified: April 2014

After corneal transplantation, topical corticosteroids are used to reduce the risk of rejection.

However, the optimal postoperative treatment regimen is unknown. In most cases, a topical steroid is administered for at least 6 months after surgery, but it remains to be determined whether potent steroids offer better protection than weak steroids. Also, the length of the treatment is debated.

Since the use of steroids is not without potential serious ocular side effects, it is of considerable importance to investigate these problems.

The study aims to examine the frequency of rejection episodes after posterior lamellar keratoplasty; specifically comparing a short course of potent steroids versus a long course of weak steroids.

Condition Intervention
Endothelial Dystrophy Secondary Bullous Keratopathy Posterior Lamellar Keratoplasty Descemet's Stripping Endothelial Keratoplasty Drug: Weak steroid (Flurolon, Allergan) Drug: Potent steroid (Maxidex, Alcon)

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Investigation of Treatment With Topical Corticosteroid After Posterior Lamellar Corneal Transplantation

Resource links provided by NLM:

Further study details as provided by Anders Ivarsen, Aarhus University Hospital:

Primary Outcome Measures:
  • Freedom from rejection [ Time Frame: 2 years ]

Enrollment: 0
Study Start Date: September 2012
Primary Completion Date: September 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Weak steroid
Initial treatment with dexamethasone 6x per day for two weeks, followed by Fluorometholone 4x per day for 2 months, 3x per day for 2 months, 2x per day for 2 months, and finally 1x per day continually during 2 years.
Drug: Weak steroid (Flurolon, Allergan)
Other Name: Flurolon, Allergan
Experimental: Potent steroid
Initially Dexamethasone 6x per day for 2 weeks followed by 4x per day for one month, 3x per day for one month, 2x per day for one month, and finally 1x per day for one month - giving a total of 4,5 months of steroid treatment.
Drug: Potent steroid (Maxidex, Alcon)
Other Name: Maxidex, Alcon


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients treated for primary or secondary corneal endothelial failure at the department of ophthalmology, Aarhus University Hospital

Exclusion Criteria:

  • Not fulfilling the above
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01682421

Department of Ophthalmology, Aarhus Universtity Hospital
Aarhus, Denmark, DK-8000
Sponsors and Collaborators
Aarhus University Hospital
  More Information

Responsible Party: Anders Ivarsen, MD, PhD, Aarhus University Hospital Identifier: NCT01682421     History of Changes
Other Study ID Numbers: AUH_DSAEK_STEROID
Study First Received: September 4, 2012
Last Updated: April 30, 2014

Additional relevant MeSH terms:
Dexamethasone acetate
BB 1101
Anti-Inflammatory Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on August 17, 2017